Skip to main content
Janos Tanyi, MD, Obstetrics & Gynecology, Philadelphia, PA, Hospital of the University of Pennsylvania

JanosLTanyiMD

Obstetrics & Gynecology Philadelphia, PA

Gynecologic Oncology

Assistant Professor, Obstetrics & Gynecology, Perelman School of Medicine

Dr. Tanyi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tanyi's full profile

Already have an account?

  • Office

    3400 Civic Center Boulevard
    3rd Floor
    Philadelphia, PA 19104
    Phone+1 215-662-3318
    Fax+1 215-349-5680
  • Is this information wrong?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2008 - 2011
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Obstetrics and Gynecology, 2004 - 2008
  • University of Debrecen Medical and Health Science Center
    University of Debrecen Medical and Health Science CenterClass of 1993

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2012 - 2026
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • PA State Medical License
    PA State Medical License 2008 - 2024
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian c... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • Positive Phase 2 Study Results Published for on Target's Intraoperative Cancer Imaging Agent
    Positive Phase 2 Study Results Published for on Target's Intraoperative Cancer Imaging AgentOctober 15th, 2019
  • IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free Survival
    IMV Inc. Presents New Positive Data from Phase 2 Monotherapy Arm of Its Decide1 Trial in Advanced Ovarian Cancer and Continued Duration of Clinical Benefits to Patients with Progression Free SurvivalJune 1st, 2019
  • Triggering an Immune Response in Ovarian Cancer
    Triggering an Immune Response in Ovarian CancerJuly 12th, 2018
  • Join now to see all

Professional Memberships

Other Languages

  • Hungarian

Hospital Affiliations